Mymetics Corporation (OTCMKTS:MYMX) Files An 8-K Entry into a Material Definitive Agreement

Mymetics Corporation (OTCMKTS:MYMX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On November 28, 2016, the registrant, Mymetics Corporation, through its Dutch subsidiary, Mymetics BV (“Mymetics”), entered into a Research Agreement (the “Agreement”), effective October 21, 2016, with Sanofi Pasteur Biologics, LLC (“Sanofi”), the vaccine division of Sanofi SA. Sanofi will evaluate the immunogenicity of influenza vaccines based on Mymetics’ proprietary virosome technology platform in pre-clinical settings compared to egg-based split vaccines. Mymetics expects to enter into a more extensive collaboration with Sanofi should the evaluation by Sanofi be positive.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement which is filed as exhibit 10.1 to this Current Report on Form 8-K.
The registrant issued a press release announcing the Agreement, a copy of which is filed as exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
10.1
Research Agreement effective October 21, 2016 between Sanofi Biologics, LLC and Mymetics BV*
99.1
Press Release dated December 1, 2016
*Portions of this exhibit 10.1 have been omitted and separately filed with the SEC with a request for confidential treatment.

About Mymetics Corporation (OTCMKTS:MYMX)

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Mymetics Corporation (OTCMKTS:MYMX) Recent Trading Information

Mymetics Corporation (OTCMKTS:MYMX) closed its last trading session 00.0000 at 0.0100 with 475 shares trading hands.

An ad to help with our costs